Irbesartan
| Evidence Level: L5 | Predicted Indications: 4 |
Table of Contents
Irbesartan: From Hypertension to Malignant Renovascular Hypertension
One-Sentence Summary
Irbesartan is an angiotensin II receptor blocker (ARB) with a well-established role in the management of hypertension. The TxGNN model predicts it may be effective for Malignant Renovascular Hypertension, but this prediction is currently supported by no clinical trials and no published literature — it rests on mechanistic reasoning alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Hypertension (based on the drug’s established ARB class; no formal marketing-authorisation text is available in this evidence pack) |
| Predicted New Indication | Malignant Renovascular Hypertension |
| TxGNN Prediction Score | 99.31% |
| Evidence Level | L5 (model prediction only, no supporting trials or literature) |
| UK Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, Irbesartan is part of the angiotensin II receptor blocker (ARB) class, and its efficacy in hypertension has been proven; mechanistically it may be applicable to malignant renovascular hypertension because both conditions involve the renin-angiotensin-aldosterone system (RAAS).
Malignant renovascular hypertension is driven by activation of the RAAS pathway, and ARBs act directly on this pathway by blocking the AT1 receptor. This gives the prediction pharmacological plausibility. However, malignant hypertension is a hypertensive emergency that is conventionally managed with intravenous antihypertensives for rapid blood pressure control; oral ARBs such as irbesartan are more appropriate for chronic management once the acute crisis has resolved, rather than as first-line emergency treatment.
It is important to note that this rationale is based on generic ARB-class pharmacology rather than drug-specific mechanistic data, since the original MOA field for irbesartan is currently a data gap. No clinical trial or literature evidence specific to this drug-disease pairing has been identified to corroborate the mechanistic hypothesis.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Safety Considerations
Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.
Note: Key warnings, contraindications and drug-drug interaction data for irbesartan are currently marked as data gaps in this evidence pack, including one Blocking severity gap (regulatory warnings/contraindications). This must be resolved before any safety assessment can proceed.
Conclusion and Next Steps
Decision: Hold
Rationale: The TxGNN prediction score is high, but the evidence level is L5 — no clinical trials or published literature directly support irbesartan for malignant renovascular hypertension, and the proposed indication is a hypertensive emergency for which oral ARBs are not standard emergency therapy. Combined with a Blocking-severity data gap on regulatory warnings/contraindications, this candidate is not ready to advance.
To proceed, the following is needed:
- Resolution of the Blocking data gap: MHRA/SmPC warnings and contraindications for irbesartan
- Mechanism of action (MOA) confirmation via DrugBank or equivalent source
- A targeted literature and clinical trial search specific to irbesartan in malignant/renovascular hypertension (the current literature set consists of unrelated general hypoxia-biology papers and does not support this indication)
- Clarification of UK marketing status, given the drug currently holds zero UK marketing authorisations in this dataset
- Clinical input on appropriateness of an oral ARB for a hypertensive-emergency indication versus chronic post-acute management
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.